📰 GeneralCNBCTuesday, November 3, 2026 at 9:35 AM UTC1h ago

A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops

Read full article at CNBC →

Originally published by CNBC. Summary and curation by DutyStation News.

← Back to News

A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

📰 Related Stories

Affordability takes center stage as Americans cast their ballots in high-stakes midterms - Fox Business

The economy is 'less K-shaped than you think' — and that's bad news for the Fed - Yahoo Finance

Trump is going to get 'trounced' in the midterms — and knows it, Anthony Scaramucci tells CNBC

Apple shares slide after weak margin outlook; Palantir slumps 8% after earnings

‘Feels like a recession’, says Bullock as cash rate hits 4.85pc - AFR

Brookfield plans for a $27 billion AI data center at UK power station